Rare Disease Drug Reviews Move From Quiet Disputes to National Debate
When Rare Disease Week opened on Feb. 23, the Food and Drug Administration announced a new initiative intended to give regulators more flexibility when reviewing treatments for rare diseases, saying traditional clinical trials may not always be feasible for conditions affecting small numbers of patients, or when waiting for more data could mean patients lose abilities that cannot be regained.
For many advocates, researchers and companies working in rare disease, the announcement was seen as a sign that the FDA recognized those challenges and was willing to adapt its approach.
But in the weeks that followed, the tone around rare disease drug approvals shifted quickly. A series of disputes, a Senate hearing, an investigation, the departure of a key FDA official, public criticism and protests from patient advocates turned what began as cautious optimism into a national debate over whether the FDA’s actions match its message, and whether the system used to approve new treatments can keep up with the realities of rare disease.
Scrutiny grows in a matter of weeks
In the span of only a few weeks, questions about how the FDA reviews rare disease treatments spread from regulatory discussions to Congress, public policy forums and patient advocacy groups.
Speaking at CNBC’s Cures Summit in New York in a session titled “Unlocking the Gridlock at the FDA,” former U.S. senator Rick Santorum said the agency’s public messaging does not match its actions.
He said Dr. Martin Makary “is an FDA commissioner who is regulating by press release. He’s telling his boss what his boss wants to hear. Meanwhile, the agency is doing the opposite of everything the press release says.”
A week earlier, lawmakers raised concerns during a Senate hearing on the approval process for rare disease drugs, where witnesses said the current system can be difficult to navigate when patient populations are small and clinical trials may not follow traditional models.
Dr. Jeremy Schmahmann, a neurologist at Massachusetts General Hospital who testified before the Senate Special Committee on Aging, said working with the agency could feel like “talking to a brick wall,” reflecting frustrations researchers say they encounter when trying to design studies the FDA will accept.
Soon after the hearing, Sen. Ron Johnson opened an investigation into several recent FDA decisions involving rare disease therapies, asking whether the agency’s standards are being applied in ways that make approval especially difficult for conditions with few patients and limited treatment options. He called the FDA’s recent review of a gene therapy for Huntington’s disease “bureaucratic idiocy.”
Frustration among patient advocates has also become visible outside the agency. Earlier this week, rare disease advocates staged a symbolic funeral outside FDA headquarters, saying the protest was meant to represent lives they believe are being lost while potential treatments remain stuck in the approval process.
Taken together, the events have pushed the conversation beyond individual drug decisions and into a broader debate over how the FDA evaluates therapies for rare diseases, and whether the current system can move fast enough when time and patient numbers are limited.
Leadership change adds to questions about the agency
The debate intensified further with the recent departure of a key FDA official involved in reviewing biologics and gene therapies, an area that includes many rare disease treatments.
Vinay Prasad, who led the agency’s Center for Biologics Evaluation and Research, is leaving the FDA after a turbulent period marked by disputes over several high-profile decisions involving vaccines, gene therapies and treatments for serious and life-threatening conditions.
His departure drew attention in policy and medical circles, where some analysts said recent controversies had exposed deeper concerns about how the agency approaches therapies for rare diseases.
In a Wall Street Journal opinion column, health-policy analyst Robert Goldberg wrote,
“Vinay Prasad’s departure from the Food and Drug Administration is an admission that something has gone wrong in how the agency handles therapies for rare and life-threatening diseases. But Dr. Prasad’s exit from the Center for Biologics Evaluation and Research doesn’t solve the problem.”
The column argued that the debate now extends beyond any single official and reflects broader questions about the culture and decision-making process inside the agency.
Questions about the system itself
The recent disputes have renewed a long-standing concern among researchers, companies and patient advocates that the FDA’s approval framework, built around large clinical trials for common diseases, does not always fit rare conditions where patient numbers are small and data are limited.
While the agency says it has tools that allow flexibility, recent decisions have raised new questions about how those standards are being applied, and whether the system can move fast enough for diseases that continue to progress while studies are still underway.
Patients’ voices now part of the debate
The widening debate has also reached patient organizations.
In a recent message to its community, the National Ataxia Foundation said the U.S. Senate Special Committee on Aging is collecting statements from patients, caregivers and clinicians about their experiences with rare disease drug development and approval as part of a congressional review of the FDA’s policies. The group told members that statements can be submitted directly to the committee at rarediseasestatements@aging.senate.gov.
Advocates say the request reflects how quickly the issue has moved beyond individual drug decisions to broader questions about the system itself, drawing in lawmakers, researchers and the families most affected by the agency’s rulings.
Whether the recent scrutiny will lead to changes in how rare disease treatments are reviewed remains unclear. But for many families, the question is no longer just whether the next therapy will be approved. It is whether the process itself can adapt in time to matter.